Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD Has $2.70 Million Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Key Points

• Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD reduced its holdings in GSK PLC by 40.1% during the first quarter, now owning 69,099 shares worth approximately $2.70 million.
• GSK recently reported $1.13 earnings per share, surpassing analyst estimates of $1.08, with revenues reaching $10.06 billion for the quarter.
• The company announced an increased quarterly dividend of $0.4216 per share, representing an annualized yield of 4.44%, up from the previous $0.39 dividend.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD trimmed its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 40.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,099 shares of the pharmaceutical company's stock after selling 46,286 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD's holdings in GSK were worth $2,703,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. First Heartland Consultants Inc. bought a new position in GSK in the 1st quarter valued at about $351,000. Assetmark Inc. increased its stake in shares of GSK by 35.6% during the first quarter. Assetmark Inc. now owns 101,903 shares of the pharmaceutical company's stock worth $3,948,000 after purchasing an additional 26,754 shares during the period. Cetera Investment Advisers lifted its holdings in GSK by 9.1% during the 1st quarter. Cetera Investment Advisers now owns 286,547 shares of the pharmaceutical company's stock worth $11,101,000 after purchasing an additional 23,948 shares during the last quarter. Avantax Advisory Services Inc. boosted its stake in GSK by 18.5% in the 1st quarter. Avantax Advisory Services Inc. now owns 122,800 shares of the pharmaceutical company's stock valued at $4,757,000 after purchasing an additional 19,147 shares during the period. Finally, Lifeworks Advisors LLC acquired a new position in GSK in the 1st quarter valued at $202,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GSK. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. BNP Paribas assumed coverage on shares of GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price on the stock. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $37.38.

GSK Stock Performance

Shares of GSK stock opened at $37.95 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21. The company has a market cap of $77.70 billion, a PE ratio of 19.56, a price-to-earnings-growth ratio of 1.56 and a beta of 0.50. The company has a 50 day moving average of $39.03 and a 200-day moving average of $37.50. GSK PLC Sponsored ADR has a 1-year low of $31.72 and a 1-year high of $44.67.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. GSK's revenue was up 2.1% compared to the same quarter last year. During the same period last year, the firm posted $0.43 earnings per share. As a group, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, July 10th. Shareholders of record on Friday, May 16th were given a $0.4216 dividend. The ex-dividend date was Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a yield of 4.44%. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is currently 88.14%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.